Trials BRAVE AA1 and BRAVE AA2 report Baricitinib to treat Alopecia Areata
Alopecia areatai.e hair loss is a known autoimmune condition affecting the scalp, eyebrows, and eyelashes, for which treatments are limited. Baricitinib, an oral selective is known to cure hair loss.
Nearly 40% of adults with alopecia areata taking baricitinib, an oral Janus kinase (JAK) 1 and 2 inhibitors, see significant hair regrowth over 52 weeks, according to updated results from two phases 3 trials presented at the American Academy of Dermatology 2022 annual meeting.
The results indicated improved response rates and hair growth among trial participants study findings are published in The New England Journal of Medicine. All patients enrolled in the two trials, called BRAVE-AA1 and BRAVE-AA2, had severe alopecia areata, defined as a Severity of Alopecia Tool (SALT) score of ≥ 50, meaning 50% or less scalp coverage.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd